Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Srinivasan Website

Ramaprasad Srinivasan, M.D., Ph.D.

Selected Publications

1)  Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
J. Clin. Oncol. 32: 431-7, 2014.
[Journal]
2)  Shuch B, Linehan WM, Srinivasan R.
Aerobic glycolysis: a novel target in kidney cancer.
Expert Rev Anticancer Ther. 13: 711-9, 2013.
[Journal]
3)  Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.
Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma.
Clin. Cancer Res. 19: 42-9, 2013.
[Journal]
4)  Linehan WM, Srinivasan R, Garcia JA.
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.
Semin. Oncol. 40: 511-20, 2013.
[Journal]
5)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
[Journal]
6)  Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ.
Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.
Am. J. Surg. Pathol. 37: 368-74, 2013.
[Journal]
7)  Linehan WM, Srinivasan R.
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
Nat Rev Clin Oncol. 10: 614-5, 2013.
[Journal]
8)  Shuch B, Bratslavsky G, Linehan WM, Srinivasan R.
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.
Oncologist. 17: 46-54, 2012.
[Journal]
9)  Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J. Urol. 188: 2063-71, 2012.
[Journal]
10)  Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R.
Targeting the mTOR pathway in Chromophobe Kidney Cancer.
J Cancer. 3: 152-7, 2012.
[Journal]
11)  Bratslavsky G, Sanford T, Srinivasan R, Aprelikova O, Liu J, Quezado M, Merino M, Linehan WM.
Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis.
J Cancer. 2: 271-9, 2011.
[Journal]
12)  Singer EA, Bratslavsky G, Middelton L, Srinivasan R, Linehan WM.
Impact of genetics on the diagnosis and treatment of renal cancer.
Curr Urol Rep. 12: 47-55, 2011.
[Journal]
13)  Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW.
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
Oncogene. 30: 4697-706, 2011.
[Journal]
14)  Sanford T, Chung PH, Reinish A, Valera V, Srinivasan R, Linehan WM, Bratslavsky G.
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.
PLoS ONE. 6: e21260, 2011.
[Journal]
15)  Brooks S, Linehan WM, Srinivasan R, Kong HH.
Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Arch Dermatol. 147: 364-5, 2011.
[Journal]
16)  Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA.
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Cancer Cell. 20: 315-27, 2011.
[Journal]
17)  Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R.
Molecular diagnosis and therapy of kidney cancer.
Annu. Rev. Med. 61: 329-43, 2010.
[Journal]
18)  Chung PH, Srinivasan R, Linehan WM, Pinto PA, Bratslavsky G.
Renal cell carcinoma with metastases to the gallbladder: four cases from the National Cancer Institute (NCI) and review of the literature.
Urol. Oncol. 30: 476-81, 2010.
[Journal]
19)  Singer EA, Bratslavsky G, Linehan WM, Srinivasan R.
Targeted therapies for non-clear renal cell carcinoma.
Targeted oncology. 2010.
[Journal]
20)  Linehan WM, Srinivasan R, Schmidt LS.
The genetic basis of kidney cancer: a metabolic disease.
Nat Rev Urol. 7: 277-85, 2010.
[Journal]
21)  Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM.
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Cancer Genet. Cytogenet. 196: 45-55, 2010.
[Journal]
22)  Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C.
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
Blood. 114: 4494-502, 2009.
[Journal]
23)  Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Neckers L, Schmidt LS, Srinivasan R.
Hereditary kidney cancer: unique opportunity for disease-based therapy.
Cancer. 115: 2252-61, 2009.
[Journal]
24)  Erdag G, Meck JM, Meloni-Ehrig A, Matyakhina L, Donohue T, Srinivasan R, Mowrey P, Kelly J, Smith A, Childs R.
Long-term persistence of nonpathogenic clonal chromosome abnormalities in donor hematopoietic cells after allogeneic stem cell transplantation.
Cancer Genet. Cytogenet. 190: 125-30, 2009.
[Journal]
25)  Srinivasan R, Armstrong AJ, Dahut W, George DJ.
Anti-angiogenic therapy in renal cell cancer.
BJU Int. 99: 1296-300, 2007.
[Journal]
26)  Srinivasan R, Linehan WM.
Antiangiogenic therapy in renal cell carcinoma: from concept to reality.
Nat Clin Pract Urol. 4: 74-5, 2007.
[Journal]
27)  Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, Torres-Cabala C, Glenn GM, Choyke P, Merino MJ, Zbar B, Pinto PA, Srinivasan R, Coleman JA, Linehan WM.
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.
J. Urol. 177: 2074-9; discussion 2079-80, 2007.
[Journal]
28)  Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L.
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
Clin. Cancer Res. 13: 671s-679s, 2007.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/15/2014.